fda drug safety communication semaglutide naion 2025 The obesity (Wegovy) conferred a significantly higher risk of ischemic optic neuropathy (ION) than any other GLP-1 agonist, including semaglutide for diabetes (Ozempic), an analysis of data showed. Added Is Semaglutide Linked to NAION?

In addition to the determination of circulating levels of dioxins which are expressed per gram lipids, there are certain specific and non-specific biomarkers indicating exposure to the dioxins

Known Unknowns & Insurance Uncertainty While FDA approval of Wegovy for MASH is a milestone, significant coverage questions remain unresolved: 1

Weight loss procedures such as calorie restriction and metabolic/bariatric surgery are known to affect bone health because they elevate bone turnover markers (BTMs) and reduce bone mineral density (BMD) [7,8,9]

Both supplements should complement evidence-based treatments under medical supervision and are not recommended as substitutes for conventional therapy in cardiovascular disease or chronic fatigue syndrome